HISTOLOGICAL DIFFERENCE BETWEEN COMPLETE RESPONDERS AND NONRESPONDERS TO INTERFERON THERAPY OF THE LIVERS OF PATIENTS WITH CHRONIC HEPATITIS-C

被引:0
|
作者
UCHIDA, T [1 ]
TAIRA, M [1 ]
SHIKATA, T [1 ]
MORIYAMA, M [1 ]
TANAKA, N [1 ]
OKUBO, H [1 ]
ARAKAWA, Y [1 ]
机构
[1] NIHON UNIV,SCH MED,DEPT INTERNAL MED,TOKYO 173,JAPAN
来源
ACTA PATHOLOGICA JAPONICA | 1993年 / 43卷 / 05期
关键词
CHRONIC HEPATITIS; HEPATITIS-C; INTERFERON; LIVER HISTOLOGY; VIRAL HEPATITIS;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Liver histology was compared in patients with chronic hepatitis C to note the differences between responders and non-responders to interferon treatment. Fifty-eight patients were administered interferon in varying doses and over various periods, and were then followed up for 1 year. According to the improvement status of serum alanine aminotransferase (ALT) levels during this period, the patients were classified into complete responders who showed complete normalization of ALT; partial responders who exhibited a significant decrease, but not complete normalization of ALT; and non-responders who did not reveal any significant decrease of ALT. Before application of the interferon treatment, liver biopsies were analyzed in four parameters and given scores from 0 to 5 for three groups in cord with no prior knowledge of the efficacy. The parameters included necroinflammation, fibrosis/lobular distortion, portal lymphocytic reaction and portal (or fibrous septal) outline destruction. Results indicated that there were no significant differences in the score of necroinflammation and portal lymphocytic reaction between the complete responder group and the non-responder group. In contrast, the complete responder group exhibited weaker fibrosis/lobular distortion and less portal outline destruction than the non-responder group. The partial responder group was more akin to the former group in these parameters. Thus, it is safe to conclude that liver histology may predict the efficacy of interferon treatment.
引用
收藏
页码:230 / 236
页数:7
相关论文
共 50 条
  • [41] Efficacy of interferon therapy for aged patients with chronic hepatitis C
    Yasuji Arase
    Hiromitsu Kumada
    Journal of Gastroenterology, 2004, 39 : 1123 - 1124
  • [42] Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C
    Huraib, S
    Iqbal, A
    Tanimu, D
    Abdullah, A
    AMERICAN JOURNAL OF NEPHROLOGY, 2001, 21 (06) : 435 - 440
  • [43] CHRONIC VIRAL-HEPATITIS AND INTERFERON - PRELIMINARY-RESULTS IN 60 PATIENTS WITH CHRONIC HEPATITIS-C AND INTRACELLULAR MECHANISMS
    BRENARD, R
    HORSMANS, Y
    GEUBEL, A
    ACTA GASTRO-ENTEROLOGICA BELGICA, 1994, 57 (3-4): : 230 - 235
  • [44] Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders
    Schiff, ER
    Dienstag, JL
    Karayalcin, S
    Grimm, IS
    Perrillo, RP
    Husa, P
    de Man, RA
    Goodman, Z
    Condreay, LD
    Crowther, LM
    Woessner, MA
    McPhillips, PJ
    Brown, NA
    JOURNAL OF HEPATOLOGY, 2003, 38 (06) : 818 - 826
  • [45] EFFICACY OF LONG-TERM RECOMBINANT INTERFERON-ALFA IN PATIENTS WITH CHRONIC HEPATITIS-C - A CLINICAL, BIOLOGICAL, HISTOLOGICAL AND IMMUNOHISTOLOGICAL STUDY
    POYNARD, T
    BEDOSSA, P
    MATHURIN, P
    NAVEAU, S
    DELFRAISSY, JF
    LEMAIGRE, G
    CHAPUT, JC
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1991, 15 (8-9): : 615 - 619
  • [46] HISTOLOGICAL OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS-C GIVEN A 60-WEEK INTERFERON ALFA-2B TREATMENT COURSE
    REICHARD, O
    GLAUMANN, H
    NORKRANS, G
    WEJSTAL, R
    FRYDEN, A
    SCHVARCZ, R
    WEILAND, O
    LIVER, 1994, 14 (04): : 169 - 174
  • [47] Combination Therapy of Active HBsAg Vaccination and Interferon-α in Interferon-α Nonresponders with Chronic Hepatitis B
    Tobias Heintges
    Wolfgang Petry
    Michaela Kaldewey
    Andreas Erhardt
    Ulrike C. Wend
    Wolfram H. Gerlich
    Claus Niederau
    Dieter Hãussinger
    Digestive Diseases and Sciences, 2001, 46 : 901 - 906
  • [48] VIRAL AND HOST FACTORS THAT CONTRIBUTE TO EFFICACY OF INTERFERON-ALPHA(2A) THERAPY IN PATIENTS WITH CHRONIC HEPATITIS-C
    MATSUMOTO, A
    TANAKA, E
    SUZUKI, T
    OGATA, H
    KIYOSAWA, K
    DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (06) : 1273 - 1280
  • [49] HLA ANTIGENS IN PATIENTS WITH CHRONIC HEPATITIS-C
    VITTE, RL
    FORTIER, C
    RICHARDET, JP
    GRIMBERT, S
    TRINCHET, JC
    BEAUGRAND, M
    LEPAGE, V
    RAFFOUX, C
    TISSUE ANTIGENS, 1995, 45 (05): : 356 - 361
  • [50] Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders
    Imai, Y.
    Tamura, S.
    Tanaka, H.
    Hiramatsu, N.
    Kiso, S.
    Doi, Y.
    Inada, M.
    Nagase, T.
    Kitada, T.
    Imanaka, K.
    Fukuda, K.
    Takehara, T.
    Kasahara, A.
    Hayashi, N.
    JOURNAL OF VIRAL HEPATITIS, 2010, 17 (03) : 185 - 191